Condition
Acne Vulgaris II or III Degree
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
100%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 3 (1)
P 4 (1)
Trial Status
Active Not Recruiting1
Unknown1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07384793Phase 4Active Not RecruitingPrimary
Comparison of Efficacy of Azithromycin Alone vs Combination of Azithromycin and Probiotics in Management of Mild to Moderate Acne Vulgaris
NCT01032499Phase 3UnknownPrimary
Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir
Showing all 2 trials